.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
US Department of Justice
Novartis
Citi
Chubb
Merck
Harvard Business School
US Army
Boehringer Ingelheim

Generated: December 13, 2017

DrugPatentWatch Database Preview

PAMELOR Drug Profile

« Back to Dashboard

Drug patent expirations by year for PAMELOR

Pharmacology for PAMELOR

Medical Subject Heading (MeSH) Categories for PAMELOR

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-003Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-002Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-004Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Mallinckrodt IncPAMELORnortriptyline hydrochlorideSOLUTION;ORAL018012-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PAMELOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinckrodt IncPAMELORnortriptyline hydrochlorideSOLUTION;ORAL018012-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinckrodt LlcPAMELORnortriptyline hydrochlorideCAPSULE;ORAL018013-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Dow
Citi
Express Scripts
Deloitte
Cipla
Novartis
Harvard Business School
Cerilliant
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot